GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy

Allergan

Status: Completed

Conditions: Ocular Hypertension; Glaucoma, Open-Angle

Treatments: Drug: Fixed combination 0.3 mg bimatoprost and 5 mg timolol

Study type: Observational

Funder types: Industry

Identifiers

NCT01628601

MAF/AGN/OPH/GLA/027

Details and patient eligibility

About

This is an observational study of patients diagnosed with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) who are insufficiently responsive to monotherapy and who are prescribed GANfort® (fixed combination of 0.3 mg bimatoprost and 5 mg timolol) by their physician.

Enrollment: 392 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of primary open angle glaucoma or ocular hypertension
• Prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol)

Exclusion criteria

• None

Trial design

392 participants in 1 patient group

POAG or OHT

Description:

Patients with POAG or OHT prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol) treatment in a dose determined by the physician prior to study entry

Treatment:

Drug: Fixed combination 0.3 mg bimatoprost and 5 mg timolol